Hydrosome Labs Study Links Ultrafine Bubble Water to Better Gut Health and Lower Inflammation
illi News/10311065

Trending...
CHICAGO , Aug. 26, 2025 ~ Chicago-based biotechnology company, Hydrosome Labs, has recently announced groundbreaking preclinical results that demonstrate the potential of their ultrafine bubble (UFB) technology to positively impact gut health. The company's UFB-treated water has been shown to shift the balance of bacteria in the gut, increase production of beneficial nutrients, and reduce inflammatory markers.

The results of a 12-week peer-reviewed study, published in the August 2025 issue of Nanomaterials, revealed significant changes in gut bacteria composition among rats that were given water infused with UFBs. Specifically, there was an increase in Bacteroidetes and a decrease in Firmicutes. Bacteroidetes are known for breaking down complex foods and producing compounds that support digestion and metabolism, while Firmicutes extract energy from food but can contribute to fat storage and inflammation when dominant. These changes were also linked to higher levels of beneficial compounds like butyrate and valerate, as well as lower levels of inflammation.

What is particularly noteworthy about these findings is that the results varied depending on the concentration of UFBs in the water. This suggests that Hydrosome Labs' UFB technology can be tailored to target specific areas of gut health. This discovery opens up new possibilities for targeted microbiome modulation.

More on illi News
According to Nick Jackowetz, PhD, Senior Vice President and Principal Scientist at Hydrosome Labs, "We observed not just incremental changes, but coordinated biological shifts once UFB concentrations reached a specific threshold - a discovery that opens up new possibilities for targeted microbiome modulation." He believes that this research could lead to functional food and beverage products that more effectively boost beneficial bacteria and reduce markers of inflammation for consumers.

The study focused on female Sprague Dawley rats and compared health and gut microbiome outcomes between those who drank water treated with Hydrosome's UFB technology and those who drank regular deionized water. The rats were housed individually under controlled conditions and had free access to standard chow and water. UFB-treated water was administered over 12 weeks, with concentrations increased midway to evaluate dose-dependent effects. Blood and fecal samples were collected at multiple time points to monitor general health, inflammatory markers, gut bacteria composition, and short-chain fatty acid production. Tissue samples were also collected at the end of the study for further examination.

More on illi News
The key findings from the study include a 122% increase in Bacteroidetes and a 43% decrease in Firmicutes among rats given high-concentration UFB water compared to those drinking regular deionized water. Additionally, there was a significant increase in beneficial short-chain fatty acids, specifically butyrate (56%) and valerate (63%), which support better gut health and overall wellness. Inflammatory markers also decreased significantly, with TNF-α falling by 84%, IL-1β decreasing by 41%, and IL-10 going down by 70% in UFB-treated rats.

Bob Jacobs, President of Hydrosome Labs, believes that this research marks a shift in the role of water in product development. "For decades, companies have treated water as a passive ingredient," he says. "Our technology effectively turns water from a filler to a functional ingredient." This change in thinking has sparked excitement among innovators and product developers.

While further studies are needed to fully understand the underlying mechanisms of how UFB-treated water influences gut microbiota and determine optimal dosing, this research highlights the potential of Hydrosome Labs' UFB technology as a novel tool for targeted gut health interventions and future therapeutic applications. It establishes foundational evidence that UFB water can create favorable conditions for beneficial gut microbiome activity, driving both metabolic and immune system improvements in a concentration-dependent manner.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on illi News